-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$43.0076.74% Upside
Genmab A/S Frequently Asked Questions
-
What analysts cover Genmab A/S?
Genmab A/S has been rated by research analysts at Morgan Stanley, BMO Capital, BTIG, H.C. Wainwright, Truist Financial, Leerink Partners in the past 90 days.